Psoriasis

New "points to consider" document lists early warning signs

Robust data from clinical trials, cohort studies still lacking

A mother brought her 7-year-old son to the doctor concerned about asymptomatic lesions that had developed on his knees over the past couple of weeks.

A 58-year-old man visited his doctor concerned about a painful rash that developed over his neck and chest earlier that day.

Rates of 90% clearance approaching 50% at 12 weeks, with 100% clearance rates as high as 33%

"Dramatic improvement" at 16 weeks with IL-23 blocker after lack of response to anti-IL-17 drug

Real-world data indicate most patients who fail a first biologic drug never obtain remission

Genetics study suggests potential for precision medicine approach with PCSK9 inhibitors

Deucravacitinib significantly outperformed apremilast in two randomized trials

Spesolimab led to complete clearance of pustules within a week in more than half of patients

Drug firm hopes to bring new specific treatment to market

Yet another risk confirmed in postmarketing study

Cross-sectional study shows Asian patients have shortest face-to-face visits

Roflumilast cream first topical agent that specifically improved intertriginous psoriasis